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Capsule summary: 
- Multiple biomarkers have been associated with female hair loss, but studies showed 
inconsistent results. 
- We identified low HDL cholesterol and low Insulin-like growth factor-1 as 
independent risk factors for female hair loss. 
- When replicated, pathways leading to female hair loss can be identified as potential 
treatment targets.   
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Abstract 
Background: Multiple biomarkers have been associated with hair loss in women, but studies 
showed inconsistent results.  
Objective: We investigated the association between markers of cardiovascular disease risk 
(e.g., serum lipid levels and hypertension) and aging (e.g., 25-hydroxyvitamin D and insulin-
like growth factor) with hair loss in a population of middle-aged women.    
Methods: In a random subgroup of 323 middle-aged women (mean age: 61.5 years) from  
the Leiden Longevity Study, hair loss was graded by three assessors using the Sinclair scale; 
women with a mean score higher than 1.5 were classified as cases with hair loss.  
Results: Every standard deviation increase in HDL cholesterol was associated with a 0.65 
times lower risk (95% confidence interval [CI]: 0.46–0.91) of hair loss; for IGF-1 the risk 
was 0.68 times lower (95% CI: 0.48–0.97) per standard deviation increase, independent of 
the other studied variables. Women with both IGF-1 and HDL cholesterol levels below the 
median of the study population had a 3.47 times higher risk (95% CI: 1.30–9.25) of having 
hair loss.  
Limitations: The observational setting limits causal inference of the findings.  
Conclusion: Low HDL cholesterol and IGF-1 were associated with a higher risk of hair loss 
in women.  
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Introduction 
Hair loss has a prevalence of approximately 70 percent in men and 30 percent in 
women under the age of 70 years
1, 2
 with androgenic alopecia as the most common form. The 
pathogenesis of hair loss, in both men and women, involves increasing numbers of 
miniaturized hair follicles together with a shorter anagen (growth) phase and longer telogen 
(rest) phase. These changes result in shorter and thin vellus-like hairs
1, 3
, and ultimately in a 
loss of hair.   
Several studies support the overall assumption that hair loss in men and hair loss in 
women are two different entities, being predominantly genetically determined in men
4, 5
 and 
mainly environmentally determined in women
6
. For example, hair loss in men starts with 
bitemporal recession, which is followed by mid-frontal hair loss and vertex baldness
2
, while 
hair loss in women (e.g., female pattern hair loss or FPHL) is predominantly characterized by 
diffuse reduction in scalp hair density on the crown and frontal scalp without recession of the 
hair-line from the forehead
1
. Furthermore, androgens clearly play a role in hair loss in men, 
but not in women
4, 7, 8
. Accordingly, randomized clinical trials on the use of finastride, a type 
II 5-alpha-reductase inhibitor which inhibits the conversion of testosterone into 
dihydrotestosterone, only improved hair growth in men and not in women
9, 10
.  
The risk of FPHL has been found to increase in those that smoke
11
, have high 
cholesterol and high triglyceride levels
12
, coronary heart disease (CHD)
13, 14
, insulin 
resistance
14-16
, metabolic syndrome
12, 14, 17
, and  blood pressure and hypertension
11
. However, 
most of these factors have been inconsistently associated with FPHL. For example, the 
association between smoking and FPHL was not observed in four other cohorts
12, 13, 17, 18
, and 
the association with insulin resistance was dependent on the presence of the metabolic 
syndrome
19
. Also, findings were often observed in univariate models, which makes it difficult 
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to determine the independence of the findings. Furthermore, studies often selected 
participants prior to inclusion
12, 14
.  
With aging, there is a decrease in several age-related domains, including physiological 
function, endocrine function, musculoskeletal function, immune function and cognitive 
function, for which different biomarkers are available
20
. The aims of this study were twofold. 
First, we investigated the association between female pattern hair loss with age, smoking, 
history of diabetes, hypertension and stroke, and available markers of specific subdomains of 
physiological function that are related to increased CVD risk, notably cardiovascular 
function, glucose metabolism, body composition and inflammation as well as with available 
endocrine markers of aging (related to the growth hormone /insulin-like growth factor-1 axis, 
hypothalamic pituitary (HPA axis), hypothalamic pituitary thyroid (HPT) axis and 25-
hydroxyvitamin D)
21
. Second, we aimed to investigate whether identified factors were 
specifically risk factors for women or also associated with hair loss in middle-aged men. 
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Methods 
Ethics statement 
This study has been approved by the Medical Ethical Committee of the Leiden 
University Medical Center. Written informed consent was obtained from all study 
participants. 
 
Study setting 
The Leiden Longevity Study was originally designed to identify genetic and 
phenotypic markers related to familial longevity. A detailed description about the design and 
recruitment strategy has been described elsewhere
22, 23
. In short, between 2002 and 2006 a 
total of 421 Caucasian families were recruited. Families were eligible for inclusion when at 
least two long-lived siblings were still alive, had the same parents and fulfilled the age 
criterion of being at least 89 years for men and 91 years for women, which represents less 
than 0.1% of the overall Dutch population in 2001. There were no selection criteria on health 
or demographic characteristics. Additionally, offspring of these nonagenarians were included, 
because proper controls at high age are lacking. The partners thereof were included as 
controls with a similar age, lifestyle and environment. 
 
Study design and population 
The study was conducted using a cross-sectional study design comprising all eligible 
female offspring and partners of the Leiden Longevity Study. Participants were included in 
this study when they had donated a non-fasted blood sample (collected between 2002 and 
2006) and when a facial photograph was taken for the assessment of the degree of hair loss 
(collected between 2006 and 2008). From a random subpopulation of 323 female participants 
also facial photographs were taken for the assessment of the degree of hair loss. These data 
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were also available for 322 male participants, which were used to study whether observed 
markers related to FPHL are sex-specific or general markers of hair loss in both sexes.  
 
Hair loss assessment 
Participants came to the research center without any makeup or having used any 
hairstyling products for the photographs. Photographs used for the assessment of hair loss 
were taken of the vertex of the head with the scalp hair parted along the midline. We used the 
average score from three assessors who gave independent assessments using the 5-point 
Sinclair scale for determining the degree of hair thinning in females
24
. We considered 
participants with a Savin score higher than 1.5 as cases with FPHL. Participants with a Savin 
score equal or below 1.5 were considered as controls. Hair loss in men was determined using 
the Hamilton score
4
, and used continuously.  
 
Assessment of determinants 
The following potential markers were studied: age, body mass index (BMI), 
percentage of body fat, systolic and diastolic blood pressure, smoking status, 25-
hydroxyvitamin D, HDL cholesterol, low-density lipoprotein (LDL) cholesterol, 
triglycerides, adiponectin, leptin, glucose, insulin, insulin-like growth factor-1 (IGF-1), 
thyroid-stimulating hormone (TSH), free triiodothyronine (fT3), high sensitivity C-reactive 
protein (hsCRP), aspartate aminotransferase (ASAT), dehydroepiandrosterone sulfate 
(DHEAS), and history of diabetes, hypertension and stroke.  
Biochemical measures. Non-fasting blood samples were drawn and processed within 
2 hours. The Cobas e411 (Roche Diagnostics, Almere, the Netherlands) was used for 
measuring 25-hydroxyvitamin D level. The levels of HDL cholesterol, triglycerides, leptin, 
adiponectin, hsCRP and glucose were measured using the Hitachi Modular P800 or the Cobas 
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Integra 800 (Roche Diagnostics, Almere, the Netherlands). LDL cholesterol was calculated 
using the Friedewald formula
25
. The Immulite 2500 from Siemens DPC (Los Angeles, CA, 
USA) was used for measuring IGF-1 and insulin. TSH and fT3 were measured on the 
Modular E170, DHEAS was measured using the Chemiluminescent Microparticle 
Immunoassay technology on a Abbott ci8200 (Abbott, Abbott Park, USA).  
 Other measures. The age at the moment of the facial photographs was used in the 
analyses. Weight (in kilograms), height (in meters), systolic and diastolic blood pressure were 
measured by research nurses at the study center. BMI was calculated by dividing weight with 
height squared. Four blood-pressure measurements (systolic and diastolic) were taken at two 
different time points maximally 2 hours apart. The mean thereof was used for analyses. The 
percentage of body fat was determined using the In-Body (720) body composition analyzer. 
A detailed description of the In-Body (720) body composition analyzer has been published 
elsewhere
26
. A lifestyle questionnaire was used to determine smoking status (current or non-
smoker). Disease history (diabetes mellitus, hypertension, and stroke) was defined on the 
basis of records of the general practitioner.  
 
Statistical analyses 
The initial analyses were only conducted in females. As the outcome FPHL was 
dichotomized, analyses were conducted with logistic regression. For the analyses, we 
considered offspring and controls as one study population. All continuous markers were 
transformed into Z-scores. Therefore, all results of these markers should be interpreted as the 
effect per standard deviation increase. We conducted the analyses using a two-step approach. 
First, we conducted analyses in which we studied all markers separately, and adjusted for 
age. Second, we conducted one multivariable analysis including the determinants that had a 
p-value below 0.1 in the univariate analysis, adjusted for age. A composite score was 
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calculated for the markers that reached statistical significance (p-value<0.05) in the 
multivariate analysis. In this score, numerical data was dichotomized based on the median of 
the study population (low/high). Participants were allowed to have missing data. Missing 
markers of cardiovascular disease or aging were estimated using multiple imputations (5 
times).  
A number of sensitivity analyses were conducted. In case of glucose and insulin, the 
univariate analyses were repeated for participants without diabetes. Furthermore, in case of 
systolic and diastolic blood pressure, the univariate analyses were repeated in participants 
without hypertension. As multiple determinants in the present study were previously 
described to be different between offspring and partners (e.g., glucose, 25-hydroxyvitamin 
D
27, 28
), analyses were additionally stratified for these groups to study potential effect 
modification by study group.  
The determinants that reached statistical significance in the multivariable analysis on 
FPHL were also studied with respect to baldness in men. For these variables, a similar 
composite score was calculated per participant. As the Hamilton score was normally 
distributed, these analyses were conducted using linear regression models.  
All statistical analyses were conducted using SPSS v.20 for Windows (SPPS Inc., 
Chicago, IL, U.S.A.). P-values below 0.05 were considered statistically significant. 
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Results 
Study characteristics 
The general characteristics of the study population are presented in Table 1. In short, 
the study population comprised women with a mean age of 61.5 years and a BMI of 26.4 
kg/m
2
; of the studied diseases, hypertension was most common (25.7%).  
 
Markers of health and disease and female hair loss 
 Of the 323 female participants, 43 (13.3%) participants were defined as cases with 
FPHL. 
The associations between the markers with FPHL are presented in Table 2. Per 
standard deviation higher level of HDL cholesterol and IGF-1, the risk of female hair loss 
was significantly lower (HDL cholesterol: 0.59 [95% CI: 0.42 – 0.83]; IGF-1: 0.64 [95% CI: 
0.45 – 0.90]). Furthermore, we observed a trend toward an association between higher 
diastolic blood pressure and higher risk of hair loss (95% confidence interval [CI]: 0.95 – 
1.86). None of the others studies variables were associated with FPHL (p-value > 0.1). The 
sensitivity analyses on glucose and insulin (excluding women with diabetes mellitus), and 
systolic and diastolic blood pressure (excluding women with hypertension) did not materially 
change the results (results not shown). Furthermore, results were similar for offspring and 
partners (results not shown). 
The observed effect estimates of diastolic blood pressure, HDL cholesterol and IGF-1 
did not change when we included these variables together in a multivariate analysis (Table 
2). One standard deviation higher level of HDL cholesterol and IGF-1 were statistically 
significantly associated with a lower risk of hair loss (HDL cholesterol: 0.65 [95% CI: 0.46 – 
0.91]; IGF-1: 0.68 [95% CI: 0.48 – 0.97]).  
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 Participants with both IGF-1 and HDL cholesterol level below the median of the study 
population had a 3.47 times higher risk to have hair loss (Figure 1), which was statistically 
significant (95% CI: 1.30 – 9.25). Participants with either a level of IGF-1 or HDL 
cholesterol level below the median of the study population also had a higher risk of hair loss, 
but this was not statistically significant. Furthermore, there was a significant trend across the 
study groups (p-valuetrend = 0.011). 
 
Association IGF-1 and HDL and hair loss in men 
 In a second analysis, a total of 322 men with a mean age of 61.1 years (SD = 6.5) 
were included. Neither IGF-1 nor HDL cholesterol level were, after adjustment for age, 
associated with a higher mean Hamilton score. Furthermore, men with a level of IGF-1 and 
HDL cholesterol lower than the median of the study population had no higher mean Hamilton 
score than males with serum levels above the median (Figure 2).  
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Discussion 
 In the present study, we aimed to assess the association between markers 
cardiovascular disease risk and aging with FPHL at middle-age. Of the studied markers, 
higher levels of HDL cholesterol and IGF-1 were associated with a lower risk of FPHL in 
univariate models. These associations remained similar in the multivariate analysis, which 
suggests that HDL cholesterol and IGF-1 were independently associated with FPHL. 
Furthermore, neither HDL cholesterol nor IGF-1 were associated with baldness in men. 
 The association between high HDL cholesterol level and less hair loss in women 
suggests a role for cardiovascular risk factors in the process of hair loss. However, the 
association between HDL cholesterol and FPHL has not been found in female European or 
Korean populations
17, 18
. Furthermore, HDL cholesterol was not associated with male 
baldness in our study population, which is similar to findings of other studies
12, 17
. A meta-
analysis on determinants of hair loss, in which hair loss in men and women was treated as the 
same phenotype, also found no association between HDL cholesterol and hair loss
14
. 
However, the heterogeneity in their results was large, which speculatively could be in part 
driven by sex differences. Hence, further studies are required to confirm the link between 
HDL cholesterol and hair loss in women.   
Although associations between cardiovascular disease or its risk factors and FPHL 
have been observed previously in a number of studies
12, 13, 15, 16
, including the present study, a 
pathogenic link has yet to be fully elucidated. Interestingly, patients with primary cicatricial 
alopecia, a class of rare inflammatory disorders characterized by the destruction of hair 
follicles and permanent hair loss, were shown to have an impaired cholesterol biosynthetic 
pathway in the skin and hair follicles
29
. Cholesterol precursors stimulated pro-inflammatory 
processes and recruitment of macrophages, which ultimately resulted in the destruction of the 
hair follicle
29
. Indeed, an accumulation of cholesterol precursors in murine skin was shown to 
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cause defects in hair growth, but was also shown to be reversible with simvastatin 
treatment
30
. Furthermore, deficits in cholesterol biosynthesis, as seen, for example, in 
congenital hemodysplasia with ichthyosiform erythroderma and limb defects and 
desmosterolosis, are also accompanied by hair loss
31
. Conversely, an inherited form of 
hypertrichoses is caused by genetic mutations in the ABCA5 leading to increased cholesterol 
levels in the lysosome
32
. Based on these studies, cholesterol metabolism might have an 
essential role in hair growth, and thus could be a potential target for treatment.  
The association between cardiovascular risk and FPHL is also supported by the trend 
between high diastolic blood pressure and increased risk of FPHL in our study population, 
although not statistically significant in the multivariable model. An association between high 
blood pressure (both systolic and diastolic) and hair loss has been observed previously in 
women
11, 12
. Again though, two other studies observed no significant link between blood 
pressure and FPHL, which highlights the contradictory results in literature
17, 18
. Indeed, as the 
association between FPHL and diastolic blood pressure was only borderline significant in this 
study, further research is required to determine whether blood pressure or correlates thereof 
are truly associated with FPHL.  
 In this study, a high level of IGF-1 was associated with a lower risk of hair loss in 
women (but not in men) independently of HDL cholesterol levels. IGF-1 has an essential role 
in hair cycle control, hair follicle development, and hair shaft differentiation
33-35
. Although 
the IGF-1 levels measured in this study were in serum, secreted levels of IGF-1 in sebum 
from the skin are strongly correlated to serum levels
36
. Hence, this data suggests that lower 
circulating IGF-1 reflects lower IGF-1 levels in the hair bulb which could reduce hair growth 
and differentiation.  In men, there is conflicting data on IGF-1 links to hair loss. Whereas we 
found no significant association between baldness in men and serum IGF-1, Platz et al
37
 
found a higher level of IGF-1  associated with a higher risk of male baldness, and 
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Panchaprateep and Asawanonda
38
 found significantly lower levels of IGF-1 secreted from 
dermal papilla cells from balding sites. Within the present study population we previously 
observed significant associations between high levels of IGF-1 and lower degree of skin 
wrinkling
39
 and a lower degree of skin pigmentation
40
, indicating a more general role of IGF-
1 in skin aging features which potentially also effects hair loss. How reduced levels of IGF-1 
could ultimately induce hair loss in women but not men is unclear and, as this is the first 
study to find a link between serum IGF-1 and FPHL, replication of these results is therefore 
warranted.   
This study has a few limitations. First, the observational setting of the study limits the 
possibility to infer causality of IGF-1 and HDL cholesterol levels with hair loss. Second, the 
serum measures were measured in serum collected approximately 4 years before photographs 
for hair loss assessment were collected. However, this could actually be a strength of the 
study as, although the stability of IGF-1 and HDL cholesterol over the years is uncertain, the 
process of hair loss takes a number of years and could be captured more precisely in studies 
with determinants assessed a number of years earlier. Third, the assessment by photographs 
gives only an approximation of the degree of hair loss, and hair color can influence the 
assessment of FPHL, as the scalp can be identified more easily with dark hair than with grey 
hair
6
; both factors could have resulted in reduced accuracy of the FPHL data. Finally, as the 
insulin and glucose levels were measured in non-fasted samples, which could be a reason for 
why we did not observe an association with insulin resistance as previously reported
15, 16
. 
Further studies using oral glucose tolerance tests (OGTT) or intravenous glucose tolerance 
tests (IGTT) are required to better investigate glycaemic control and FPHL.   
 In conclusion, a higher level of IGF-1 and HDL cholesterol were found to be 
independently associated with a higher degree in hair loss in middle-aged women. Given the 
limitations of the present study and the contradictory results present in the literature, larger 
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studies are required to confirm the association between IGF-1, HDL cholesterol and FPHL. 
Furthermore, additional studies are required to elucidate whether circulating HDL cholesterol 
and IGF-1 levels reflect levels in the hair bulb, and how reduced levels could induce hair loss.  
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Table 1: Characteristics of the study population 
 Total (N = 323) 
General characteristics  
Age (years) 61.5 ± 6.0 
Body mass index (kg/m
2
) 26.4 ± 4.7 
Body fat percentage 35.1 ± 7.4 
Systolic blood pressure (mmHg)
 
140 ± 21 
Diastolic blood pressure (mmHg)
 
82 ± 11 
Current smoking, n (%) 35 (10.8) 
Non-fasted serum markers  
25-hydroxyvitamin D (ng/mL), median (IQR) 42.7 (38.0 – 48.7) 
High density lipoprotein (mmol/L)
 
1.6 ± 0.5 
Low density lipoprotein (mmol/L) 3.4 ± 1.0 
Triglycerides (mmol/L), median (IQR) 1.40 (1.0 – 2.1) 
Adiponectin (mg/L), median (IQR) 6.1 (4.6 – 8.6) 
Leptin (ng/mL), median (IQR) 22.4 (11.7 – 39.8) 
Glucose (mmol/L) 5.9 ± 1.2 
Insulin (mU/L), median (IQR) 16.0 (10.0 – 29.0) 
Insulin-like growth factor-1 (nmol/L)
 
17.2 ± 5.1 
Thyroid-stimulating hormone (mU/L), median (IQR)
 
1.7 (1.1 – 2.5) 
Free Triiodothyronine (pmol/L)
 
3.9 ± 0.7 
C-reactive protein (mg/L) 1.3 (0.7 – 3.1) 
Aspartate aminotransferase (U/L) 19.0 (15.0 – 25.0) 
Dehydroepiandrosterone sulfate (μmol/L) 3.1 (1.9 – 4.7) 
Disease history  
Diabetes, n (%) 14 (4.3) 
Hypertension, n (%) 83 (25.7) 
Stroke, n (%) 5 (1.5) 
All data is presented with mean ± SD unless otherwise stated. 
Abbreviations: IQR, interquartile range 
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Table 2: Association between markers of health and aging and FPHL  
 Univariate model  Multivariate model 
 OR 95% CI  OR 95% CI 
General characteristics      
  Age 1.23 0.89 – 1.71  1.15 0.82 – 1.61 
Body mass index 1.14 0.82 – 1.58    
Body fat percentage 1.22 0.87 – 1.70    
Systolic blood pressure
 
1.29 0.91 – 1.84    
Diastolic blood pressure
 
1.33 0.95 – 1.86*  1.28 0.91 – 1.82 
Smoking, yes 1.00  0.34 – 2.95    
Non-fasted serum markers      
25-hydroxyvitamin D 0.72 0.68 – 1.30    
High density lipoprotein
 
0.59 0.42 – 0.83†  0.65 0.46 – 0.91 
Low density lipoprotein 1.03 0.74 – 1.43    
Triglycerides 1.13 0.81 – 1.57    
Adiponectin 0.92 0.67 – 1.28    
Leptin 1.15 0.83 – 1.60    
Glucose 1.19 0.85 – 1.67    
Insulin 1.23 0.88 – 1.72    
Insulin-like growth factor 1
 
0.64 0.45 – 0.90†  0.68 0.48 – 0.97 
Thyroid-stimulating hormone
 
0.86 0.62 – 1.19    
Free Triiodothyronine
 
0.96  0.70 – 1.33    
High-sensitivity C-reactive protein 1.31 0.94 – 1.82    
Aspartate aminotransferase 1.14 0.81 – 1.60    
Dehydroepiandrosterone sulfate 0.99 0.69 – 1.43    
Disease history      
Diabetes, yes 1.05 0.23 – 4.89    
Hypertension, yes 1.05 0.51 – 2.19    
Stroke, yes 1.59 0.17 – 14.6    
Results depicted at the relative risk of a standard deviation increase of a determinant or as 
indicated otherwise. All analyses were adjusted for chronological age. Abbreviations: CI, 
confidence interval; OR, odds ratio. 
* 
p-value < 0.1. 
† 
p-value < 0.05. 
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Figure 1: IGF-1 and HDL status (low and high) and risk of female pattern hair loss 
Abbreviations: h, high; HDL, high-density lipoprotein; IGF-1, insulin-like growth factor-1; l, 
low. 
*
) 
 
p-value < 0.05 with respect to the reference group. Analysis was adjusted for age. 
Low IGF-1, range between 6.49 and 16.6 nmol/L; high IGF-1, range between 16.8 and 37.4 
nmol/L; low HDL cholesterol, range between 0.42 and 1.57 mmol/L; high HDL cholesterol, 
range between 1.58 and 3.24 mmol/L. In the high IGF-1 and high HDL group, there were 6 
cases of female pattern hair loss. On both the high IGF-1 and low HDL as well as the low 
IGF-1 and high HDL, there were 9 cases. In the low IGF-1 and low HDL, there were 19 
cases.   
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Figure 2: IGF-1 and HDL status (low and high) and the mean degree of hair loss in men  
Abbreviations: h, high; HDL, high-density lipoprotein; IGF-1, insulin-like growth factor-1; l, 
low; SE, standard error of the mean. Results depicted as the mean Hamilton score and the 
standard error of the mean. Analysis adjusted for age. Low IGF-1, range between 3.90 and 
16.9 nmol/L; high IGF-1, range between 17.0 and 35.5 nmol/L; low HDL cholesterol, range 
between 0.18 and 1.20 mmol/L; high HDL cholesterol, range between 1.21 and 2.51 mmol/L. 
A total of 86 participants were in the high IGF-1 and high HDL group. There were 75 
participants in the group with low IGF-1 and high HDL, and 74 participants in the group with 
high IGF-1 and low HDL. 87 participants had a low IGF-1 and a low HDL.  
